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INTRODUCTION
The number of elderly people is constantly growing world
wide and it will grow in the future. In 2006, 10% of the
population was over 60 years old, and in 2050, the propor-
tion will reach 21%. The male longevity is less than of a fe-
male. In Latvia the human longevity is one of the lowest in
Europe — 67 years (Anonymous, 2007). In recent years,
there have been a lot of investigations on age-related sexual
hormone changes in men. Women are known to have a
menopause sooner or later when the ovaries stop producing
estrogens. In men when they get older the secretion of tes-
tosterone reduces, but the level of changes is very individ-
ual and not all men fall below the physiological norm. If,
however, testosterone is deficient, pathological changes in
men cause the development of various chronic diseases and
also lower the quality of life.
The problem we are investigating is closely related to the
necessity to improve the quality of life in men after the age
of 40.
PATHOLOGICAL PHYSIOLOGY, DEFINITION
During aging, the number of Leyding cells that secrete tes-
tosterone is reduced in the testicles. Men aged 50–70 have
40% less Leyding cells than men at the age of 20–30 and its
volume also falls to 40% (Neaves et al., 1984). Experiments
on animals prove that the enzyme secretion that takes part
in testosterone synthesis was reduced in aging rats (Gooren,
2009). Pathological changes are seen in the hypothalamic-
hypophyseal axis: the normal release of free gonadotrope
hormone and its supply to the hypothalumus is affected. As
a result, secretion of this luteinizing hormone (LH) also
changes, characterised by a higher frequency but lower am-
plitude, which influences testosterone synthesis in the testi-
cles. With age, the synthesis of other kinds of hormones is
also affected. Melatonin secretion is reduced, which causes
sleep disorders in elderly men. Somatotropic hormone se-
cretion is also reduced. Although the secretion of insulin is
not affected, the tissue susceptibility to insulin is reduced
with age. However, the cortisol level is not reduced
(Gooren, 2009).
Testosterone includes free testosterone (1–3%), albumin-
bound testosterone (40–50%) and sex hormone binding
globulin (SHBG) bound testosterone (50–60%). The former
testosterone fractions are active (bio-accessible), and the
latter is inactive. After the age of 40, the level of free testos-
terone declines by 2.8% on average every year. The total
testosterone level reduces by 1.6%, the level of albumin-
bound testosterone by 2.5%, but the level of SHBG in-
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creases by 1.3% a year (Feldman et al., 2002). In general,
this level of physiological testosterone does not cause any
problems. The problems appear when the testosterone level
falls below the physiological norm. Pathologic reduction of
testosterone level occurs due to chronic diseases (such as
coronary heart disease, diabetes mellitus, metabolic syn-
drome, etc.) and/or inappropriate lifestyle (sedentary life-
style, adiposity). A complex of symptoms, which develop in
these cases is termed ‘late-onset hypogonadism’ (LOH).
Actually, this is accelerated, but not physiological, aging.
Thus collectively, LOH is an age-related clinical and bio-
chemical syndrome, which can be characterised by typical
symptoms and a reduced level of serum testosterone. As a
result, the LOH causes life quality to worsen and negatively
affects functions of various organs (Morales and Lunenfeld,
2002).
Regarding pathogenesis, LOH is considered as mixed origin
hypogonadism, and includes mechanisms of both primary
and secondary hypogonadism. Primary mechanisms include
the decrease of the testosterone production in testes due to
the involution of Leidig cells. Secondary mechanisms in-
clude decreased secretion of the gonadotrophin releasing
hormone by the hypothalamus, and more frequent but irreg-
ular luteinizing hormone pulses with lower amplitude.
Therefore, the assessment of the gonadotropic hormones is
recommended to determine the effect on to pituitary func-
tion in LOH males.
Testosterone-related organs are brain, cardiovascular sys-
tem, muscles, adrenals, liver, penis and prostate. LOH
symptoms are non-specific and depend on the male’s age,
disease history as well as the degree and length of testoster-
one deficiency. Nevertheless, LOH is known to cause
changes in most male organism systems.
LOH AND BONE DENSITY
Androgens regulate muscle mass and body build by affect-
ing bone mineral density. Most investigations have indi-
cated the presence of androgen receptors in osteoblasts, os-
teoclasts, osteocytes, and chondrocytes. Experimental in
vitro studies show that androgen influences osteoblast
proliferation, differentiation and mineralisation, as well as
production of various cytokins, such as IGF-1, an autocrine-
paracrine regulator of sexual steroid anabolic effect. Andro-
gens inhibit osteoclastogenesis and bone resorption and
stimulate bone formation by increasing periostal synthesis
(Isidori et al., 2005). Due to LOH, bone mineral density de-
creases leading to osteoporosis. The reduction of bone min-
eral density increases risk of bone fractures. Hypogonadism
in elderly men is related to increased fracture risk (Boonen
et al., 1997; Stanley et al., 1991). In a study performed in
USA, which included 78 men with femoral fractures at the
age over 65 years, who received medical care at home, it
was found that femoral fractures were four times more fre-
quent in men suffering from hypogonadism (Boonen et al.,
1997; Stanley et al., 1991). Also, vice versa, analysing 110
men with osteoporosis and 106 with normal bone mineral
density, Brazilian researchers observed that 25% men with
osteoporosis and only 12.2 % men with normal bone min-
eral density had hypogonadism (Clapauch et al., 2008). Tes-
tosterone replacement therapy (TRT) is effective in men
with hypogonadism: it increases bone mineral density espe-
cially in the vertebrae lumbale, where fractures are most
frerquent in cases of osteoporosis (Isidori et al., 2005).
LOH AND BODY BUILD
LOH causes changes in male body build by decreased mus-
cular mass and strength (Morley et al., 2001). This makes
elderly people dependent on others: when muscular strength
decreases, it is difficult for the people to carry out daily ac-
tivities. Muscular regression occurs in 13.5% of people
aged over 70, and reaches 29% incidence at the age over 80
(Morley et al., 2001). Testosterone, dihydrotestosterone and
somatotropic hormone play an important part in the devel-
opment of muscle deficiency. TRT in elderly men increases
muscular mass and decreases adiposity.
Visceral adiposity tends to increase in patients with LOH,
and is an independent risk factor for insulin resistance and
cardiovascular disease. Adiposity is one of the most wide
spread chronic diseases today affecting 9–30% of adults
globally (Butrova, 1999). Adiposity not only increases fat
amount in the organism, but also influences its distribution
in different body parts. It is considered that increased fat ac-
cumulation in the abdominal region is an independent risk
factor for insulin resistance and type-2 diabetes. In clinical
practice abdominal obesity is diagnosed when the waist is
over 94 cm in males and over 80 cm in females. Computer
tomography and magnetic resonance methods have demon-
strated two kinds of obesity: subcutaneous abdominal and
visceral (in organs). Visceral-type adiposity is associated
with the highest risk of complications. Etiology of visceral
adiposity leads to genetically predisposed inactive lifestyles.
Sedentary lifestyle as well as the excessive use of fats and
carbohydrates in the diet leads to the excessive fat accumu-
lation in the abdomen region, which in turn causes insulin
resistance and hyperinsulinemia, the predictor of type-2 dia-
betes. In addition, excessive visceral adipose tissue accumu-
lation is related to the atherogenic lipid profile: hyper-
triglycerydemia and increased level of apolipoprotein B.
Changes in the thrombolytic system occur, increasing the
risk of thrombosis (Butrova, 1999). The factors mentioned
above lead to increased incidence of cardiovascular disor-
ders (Fox et al., 2009; Ho et al., 2009).
In the case of abdominal adiposity, the insulin resistance is
associated with compensatory hyperinsulinemia (Butrova,
1999). In recent years, it was discovered that adipose tis-
sues, which carry out endocrine and paracrine functions,
produce biologically active substances that influence tissue
susceptibility to insulin. Enlarged adipocytes manufacture a
great amount of cytokines, particularly TNF- and leptin.
TNF- affects insulin interaction with receptors and also in-
creases intercellular glucose transport. In liver leptin re-
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duces the action of insulin and also possesses autocrine ac-
tion increasing transport of glucose by insulin stimulation.
Intensive lipolysis in visceral adipocytes releases free lipoic
acid (FLA) into the portal system and liver, where under the
influence of FLA binding of insulin with hepatocytes be-
comes disrupted. The clearance of metabolic insulin in liver
becomes affected, causing systemic hyperinsulinemia. In
turn, hyperinsulinemia strengthens insulin resistance in
muscles due to impairment of the autoregulation of insulin
receptor. FLA is also a substrate for triglyceride secretion
and its increased concentration causes triglycerydemia. As a
result, the so-called metabolic syndrome develops, which
includes insulin resistance, abdominal obesity, and arterial
hypertension (Butrova, 1999). Its development considerably
increases risk of cardiovascular diseases and their complica-
tions. The use of testosterone medicine reduces the amount
of fats in the organism and adiposity in men with hypo-
gonadism (Kapoor et al., 2006). Therefore, the risk of car-
diovascular disease should be also reduced (Morales and
Lunenfeld, 2002; Kapoor et al., 2006). The use of testoster-
one for 12 month in men with hypogonadism and angina
pectoris was shown to increase time to ischemia, decreased
body mass index and triglyceride level (Mathur et al.,
2009). The underlying mechanism has been investigated in
various small-range studies but large-range research is still
required (Morales and Lunenfeld, 2002; Sarkar, 2009)
LOH AND THE CARDIOVASCULAR SYSTEM
In recent years, there has been increased interest in the ac-
tion of androgens on the cardiovascular system (CVS) and
atherosclerosis development. Androgen receptors are found
in the endothelial and smooth muscular cells of blood ves-
sels. Endothelial cells become activated if the blood-vessels
are damaged and this favours the formation of athero-
sclerotic plaque. However, androgens have impact on this
process. Testosterone affects vasoconstriction and vasodil-
atation and nitric oxide (NO) synthesis. Generally, testoster-
one reduces endothelial dysfunction and promotes the de-
crease of vasospasm of coronary blood vessels, rupture of
atherosclerotic plaque and thrombosis (Isidori et al., 2005).
Studies show that there is negative correlation between the
level of endogenous androgen and development of athero-
sclerosis (Manolakou et al., 2009). Castrated animals fed by
cholesterol had faster atherosclerosis progression, which
was reduced with the onset of testosterone replacement
therapy (Netteship et al., 2009) The testosterone level is in-
versely proportional to atherosclerosis risk in elderly men
(Hak et al., 2002). Men with stenosis of at least 75% of one
coronary artery had a lower testosterone level than men
without coronary stenosis. 50% of men with stenosis have a
hypogonadal bioactive testosterone level (Phillips et al.,
1994). Several studies have investigated the effect of TRT
on CVS and cardiovascular risk. Jaffe (1977) observed that
testosterone therapy reduced ST depression, shown on an
electrocardiogram, by 32% after four weeks and by 51% af-
ter eight weeks of treatment, compared with placebo
controlo. Webb and his co-authors (1999) showed that infu-
sion of a supraphysiological dose of testosterone into the
coronary artery significantly increased the diameter of the
coronary and brachial arteries and increased blood flow.
Various studies with placebo controls have shown that TRT
improves subjective state of the patients with cardiovascular
disease and objective criteria as well. Therefore, the TRT is
recommended to patients with testosterone deficiency and
cardiovascular diseases if there are no contraindications.
LOH AND THE COGNITIVE FUNCTION
As a consequence of LOH, male cognitive function wors-
ens: poor memory, concentration power and dementia signs.
The level of plasma testosterone is lower in patients with
Alzheimer disease than in healthy men. The number of de-
pressive cases increases in elderly men. Although cases of
major depression are not observed very often, one of the
most common diseases at that age is dysthimia. Men with
dysthimia have a lower testosterone level than healthy men
(Schweiger et al., 1999). In studies on men who underwent
chemical castration to prostate cancer, concentration and
memory worsened. Studies examining the correlation be-
tween the level of testosterone in serum and cognitive func-
tions are contradictory, but they do tend to suggest that a
decrease of the level of endogenous testosterone causes re-
duction of cognitive ability in the elderly men (Beauchet,
2006). Randomised placebo controlled studies show that
TRT tends to be fairly effective in relation to different cog-
nitive functions both in hypogonadal and eigonodal elderly
men. Similar results were obtained in men with Alzheimer
disease and mild cognitive impairment. However, these
studies involved small cohorts of patients and possessed dif-
ferent structure and methodology. Therefore, to make more
definite conclusions on the TRT action on the cognitive
functions, further research in larger populations is necessary
(Beauchet, 2006).
LOH AND HAEMATOPOESIS
LOH causes changes in haematopoesis. The haemoglobin
level is known to decrease with age. In elderly men the
level of endogenous testosterone is correlated with the level
of haemoglobin. In a study on elderly men, haematokrit was
observed to have 39.9% incidence in hypogonadal and
45.6% in eigonadal men (Ellegala et al., 2003). Grossman
with co-authors (2009) investigated 464 men with type-2 di-
abetes and found a lower testosterone level to be associated
with anaemia. Similarly, in the investigation of 492 healthy
men testosterone concentration was found to affect the hae-
moglobin level in men of different age groups (Yeap et al.,
2008). There is little data in the literature on the effect of
TRT on the haemoglobin level in hypogonadal men. In a
study on 40 patients with kidney insufficiency, who under-
went haemodialysis, interaction of TRT with erythropoetin
(a medicine for treating anaemia) was not found (Brocken-
brough et al., 2006). Further thorough studies are necessary
to investigate the action of TRT on haematopoesis.
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LOH AND THE SEXUAL FUNCTION
LOH reduces the male sexual function. Adequate sexual
function has an important role in an elderly male’s life. The
longer his sexual life is, the longer he feels glad, perfect and
optimistic. An adequate sexual life is known to maintain
both physical and mental health in a good state. When a
person gets older, his libido decreases, while the frequency
of erectile dysfunction increases. A reduced testosterone
level is associated with a reduced libido. To restore normal
libido, it is necessary to obtain a normal testosterone level
(Davidson et al., 1983). There is no precise data on the in-
fluence of the testosterone level on erectile function. Some
publications mention that LOH influences only libido
(Zitzman and Nieschlag, 2003). Other publications suggest
that, as a result of TAT, erectile function decreases in more
than 50% of cases (Yassin and Saad, 2007). It was also
shown that almost all men have increased libido. In guide-
lines on the treatment of LOH, it is mentioned that men,
both with decreased libido and/or erectile dysfunction and
reduced testosterone level, are recommended to undergo
TRT.
LOH TREATMENT
Taking into account the negative influence of LOH on dif-
ferent organs and system functions, it is important to know
in which cases and how this syndrome should be treated.
According to the International Society for the Study of the
Aging Males, the published guidelines of the year 2009
(Wang et al., 2009) recommend LOH diagnosis that should
be based on clinical symptoms (such as decreased libido,
erectile dysfunction, reduced muscular mass and strength,
increased fat accumulation in the body, reduced bone min-
eral density, osteoporosis, depression) and confirmed by
laboratory tests showing deficiency of the total or free tes-
tosterone. Testosterone deficiency needs to be confirmed by
laboratory studies repeatedly.
Serum samples for the testosterone indication must be used
from 7 to 11 a.m. If the total testosterone level is over 12
nmol/l (350 ng/dl), testosterone replacement therapy is not
necessary. If the testosterone level is below 8 nmol/l (230
ng/dl), TRT is indicated. If the testosterone level is at a bor-
der-line level (from 8 to 12 nmol/l), individual solution is
necessary considering both clinical symptoms and possible
treatment outcome and risks. For TRT indication, the level
of free testosterone is not precisely defined. It is considered
that if the free testosterone concentration is < 225 pmol/l
(65 pg/ml), TRT indication can be considered.
TRT is absolutely contra-indicated if a man suffers from
prostate or thoracic gland carcinoma. In cases of erythro-
cytosis (haematocrit > 52%), severe heart failure, marked
prostate benign hyperplasia with the obstruction of urine
pathways, obstructive sleep apnoe syndrome, TRT is rela-
tively contra-indicated and can be started after treatment.
When LOH is being treated, thorough patient monitoring is
required, including digital rectal examination (DRE) and
prostate-specific antigen (PSA), which should be performed
at 3–6 months and 12 months in the first treatment year. If
treatment is being continued, PSA should be estimated once
a year. TRT is not considered to cause development of pros-
tate cancer, but it can promote growth of an existing carci-
noma. As prostate carcinoma has a high metastasis risk al-
ready at the first stage of disease, it is necessary to perform
DRE and determine the PSA level in blood at least once ev-
ery six months.
Erythrocytosis is described as a side-effect of the TRT.
Therefore, it is necessary to measure total blood count at
3–4 and 12 months in the first treatment year, and subse-
quently, once a year.
CONCLUSION
LOH is a syndrome that causes serious impairment in the
male organism. To diagnose LOH, confirmation of clinical
symptoms and laboratory studies is needed. Before starting
testosterone replacement therapy, it is necessary to consider
possible outcome and risk and to inform the patient about
the advantages of the TRT and its possible side-effects. If
the TRT course has no regression of the symptoms, the
cause of the existing symptoms should be considered. As
male’s average lifespan is very low in Latvia, it is necessary
to develop and introduce into clinical practice a screening
diagnostic algorithm of LOH for males after the age of 40.
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VÇLÎNI SÂCIES HIPOGONÂDISMS: PROBLÇMAS APSKATS
Rakstâ aplûkota vçlîni sâkuða hipogonâdisma (VSH) problçma. VSH ir klînisks un bioíîmisks sindroms, kas saistîts ar novecoðanos un
raksturojas ar tipiskiem simptomiem un samazinâtu seruma testosterona lîmeni. Tâ rezultâtâ pasliktinâs dzîves kvalitâte un tiek negatîvi
ietekmçtas daþâdu orgânu funkcijas. VSH diagnosticç, ja testosterona lîmenis ir zem 8 nmol/l (230 ng/dl) vai testosterons atrodas
robeþlîmenî (no 8 lîdz 12 nmol/l) un ir VSH kîniskie simptomi (samazinâts libido, erektilâ disfunkcija, samazinâta muskuïu masa un spçks,
paaugstinâts tauku uzkrâjums íermenî, pazeminâts kaulu minerâlblîvums, osteoporoze, depresija). VSH pacientiem indicçta
testosteronaizvietojoðâ terapija.
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